Prognostic significance and molecular mechanism of ATP-binding cassette subfamily C member 4 in resistance to neoadjuvant radiotherapy of locally advanced rectal carcinoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Yu, Zhiqi ^a   Zhang, Chang ^a   Chai, Rui ^c   Du, Yan ^b   Gao, Xianhua ^a   Xing, Junjie ^a   Yu, Enda ^a   Zhang, Wei ^a   Zhang, Xiaoqing ^a   Cao, Guangwen ^b   Fu, Chuangang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PROTEIN P53; ABCC4 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECTUM CARCINOMA; RNA INTERFERENCE; TUMOR DIFFERENTIATION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; METABOLISM; NUDE MOUSE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECTAL NEOPLASMS;

ANIMALS; CELL DIVISION; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS;

EID: 84898605111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085446     Document Type: Article

References (32)

1. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, et al. (2012) Rectal cancer. J Natl Compr Canc Netw 10:1528-1564.
2. Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, et al. (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575-582.
3. Willett CG, Duda DG, Di Tomaso E, Boucher Y, Ancukiewicz M, et al. (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27:3020-3026.
4. Fu CG, Tominaga O, Nagawa H, Nita ME, Masaki T, et al. (1998) Role of p53 and p21/WAF1 detection in patient selection for (Pubitemid 28044878)
5. Yu ZQ, Zhang C, Wang H, Lao XY, Chai R, et al. (2013) Downregulation of ATP-binding cassette subfamily C member 4 increases sensitivity to neoadjuvant radiotherapy for locally advanced rectal carcinoma. Dis Colon Rectum 56:600-608.
6. Wittgen HG, Van Den Heuvel JJ, Krieger E, Schaftenaar G, Russel FG, et al. (2012) Phenylalanine 368 of multidrug resistance-associated protein 4 (MRP4/ABCC4) plays a crucial role in substrate-specific transport activity. Biochem Pharmacol 84:366-373.
7. Marquez B, Ameye G, Vallet CM, Tulkens PM, Poirel HA, et al. (2011) Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin. PLoS One 6:e28368.
8. Huynh T, Norris MD, Haber M, Henderson MJ (2012) ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol 2:178.
9. Russel FG, Koenderink JB, Masereeuw R (2008) Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29:200-207.
10. Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, Tien Kuo M (2001) Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol 61:555-563. (Pubitemid 32178489)
11. Li X, Tan X, Yu Y, Chen H, Chang W, et al. (2011) D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Cancer 117:4201-4211.
12. Chang W, Wu L, Cao F, Liu Y, Ma L, et al. (2011) Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clin Cancer Res 17:5715-5724.
13. Ji-Fu E, Xing JJ, Hao LQ, Fu CG (2012) Suppression of lung cancer metastasisrelated protein 1 (LCMR1) inhibits the growth of colorectal cancer cells. Mol Biol Rep 39:3675-3681.
14. Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, et al. (2011) Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12, 676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47:990-996.
15. Caricato M, Borzomati D, Ausania F, Valeri S, Rosignoli A, et al. (2006) Prognostic factors after surgery for locally recurrent rectal cancer: an overview. Eur J Surg Oncol 32:126-132. (Pubitemid 43257110)
16. Jakob C, Aust DE, Liebscher B, Baretton GB, Datta K, et al. (2011) Lymphangiogenesis in regional lymph nodes is an independent prognostic marker in rectal cancer patients after neoadjuvant treatment. PLoS One 6:e27402.
17. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, et al. (2009) NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw 7:838-881.
18. Gradilone A, Pulcinelli FM, Lotti LV, Trifirò E, Martino S, et al. (2008) Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets 8:414-420.
19. Muller PA, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15:2-8.
20. Lu C, El-Deiry WS (2009) Targeting p53 for enhanced radio- and chemosensitivity. Apoptosis 14:597-606.
21. Fukushima Y, Oshika Y, Tokunaga T, Hatanaka H, Tomisawa M, et al. (1999) Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer. Eur J Cancer 35:935-938. (Pubitemid 29277127)
22. Candas D, Fan M, Nantajit D, Vaughan AT, Murley JS, et al. (2013) CyclinB1/Cdk1 phosphorylates mitochondrial antioxidant MnSOD in cell adaptive response to radiation stress. J Mol Cell Biol 5:166-175.
23. Nantajit D, Fan M, Duru N, Wen Y, Reed JC, et al. (2010) Cyclin B1/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. PLoS One 5:e12341.
24. Sassi Y, Abi-Gerges A, Fauconnier J, Mougenot N, Reiken S, et al. (2012) Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J 26:1009-1017.
25. Witkowski G, Rola R, Szulczyk P (2012) Effect of cyclic adenosine monophosphate on the G protein-dependent inward rectifier K (+)-like channel current in medial prefrontal cortex pyramidal neurons. J Physiol Pharmacol 63; 457-462.
26. Kim C, Cheng CY, Saldanha SA, Taylor SS (2007) PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell 130:1032-1043. (Pubitemid 47410267)
27. Haste NM, Talabani H, Doo A, Merckx A, Langsley G, et al. (2012) Exploring the Plasmodium falciparum cyclic-adenosine monophosphate (cAMP)-dependent protein kinase (PfPKA) as a therapeutic target. Microbes Infect 14:838-850.
28. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, et al. (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286:6979-6988.
29. Jorgensen TJ (2009) Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 8:665-670.
30. Langerak P, Russell P (2011) Regulatory networks integrating cell cycle control with DNA damage checkpoints and double-strand break repair. Philos Trans R Soc Lond B Biol Sci 366:3562-3571.
31. Zhao L, Bode AM, Cao Y, Dong Z (2012) Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis 33:2220-2227.
32. Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59:928-942. (Pubitemid 38834285)